Metformin modifies plasma microbial-derived extracellular vesicles in polycystic ovary syndrome with insulin resistance

Table 1 Sample characteristics of PCOS-IR before and after treatment

	Age, year 32 (27, 37.5)	FBG, mmol/L		HOMA-IR		BMI		TEST		E2
		BF	AF	BF	AF	BF	AF	BF	AF	BF	AF
		5.72 (5.64, 5.97)	5.38 (5.30, 5.59)	5.54 (4.80, 8.52)	3.93 (3.11, 4.27)	27.30 (26.90, 28.20)	27.10 (26.70, 28.00)	1.71 (1.53, 1.81)	1.54 (1.36, 1.59)	0.12 (0.12, 0.12)	0.24 (0.11, 0.49)
Patient-1	32	5.72	5.30	8.52	3.11	27.30	26.70	1.53	1.36	0.12	0.11
Patient-2	28	5.64	5.17	5.54	4.27	28.20	28.00	1.81	1.59	0.12	0.49
Patient-3	36	6.04	5.59	10.07	7.69	34.10	31.93	1.22	0.87	0.10	0.24
Patient-4	39	5.63	5.38	4.80	2.30	26.80	24.30	1.71	1.54	0.13	0.65
Patient-5	26	5.97	5.66	4.78	3.93	26.90	27.10	2.42	2.02	0.12	0.10
P Value		0.043		0.043		0.104		0.042		0.225

Data are expressed as value or median (interquartile range)
FBG, fasting plasma glucose; HOMA-IR, Homeostatic Model Assessment for Insulin Resistancel; BMI, Body Mass Index; TEST, Testosterone; E2, Estradiol
BF, before metformin treatment; AF, after metformin treatment

ISSN: 1757-2215